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Introduction: The CMAP scan is a surface EMG method based on the successive activation of motor units.
It provides information about reinnervation processes, the number of functional motor units and nerve
excitability. The CMAP scan has potential value as a follow-up tool in monitoring disease progression,
recovery or aging of the peripheral nerves. In this study, we assessed its interobserver and different-
day reproducibility.
Methods: Two investigators recorded CMAP scans in ten healthy subjects, each on two different days.
Intraclass correlation coefﬁcients (ICCs) and coefﬁcients of variation (CoVs) were calculated for the
parameters extracted from the CMAP scan.
Results: All CMAP scan parameters had a good different day (ICCs >0.8 and CoVs <15%) and interobserver
reproducibility (ICCs >0.7 and CoVs 615%). Different-day reproducibility was better than interobserver
reproducibility.
Conclusion: CMAP scan test–retest variability is small, suggesting that as a follow-up tool it may be sen-
sitive to fairly small (patho)physiological changes in the studied variables.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The compound muscle action potential (CMAP) scan is a sur-
face EMG method in which the build-up of the CMAP is visualized.
It is based on the successive activation of motor units (MUs)
through transcutaneous electrical stimulation. Each MU has a
different stimulus intensity (SI) at which it can be activated.
Therefore, a gradual increase in SI from threshold (the SI at which
the MU with the lowest threshold is activated) to supramaximal
(the SI that elicits a maximum CMAP) values will result in succes-
sive activation of all MUs in the muscle. Plotting the elicited CMAP
amplitudes versus the corresponding SIs results in a stimulus–
response curve (Fig. 1A). This curve is sometimes used to study
excitability properties of peripheral nerves (Brismar, 1985;
Meulstee et al., 1997; Ginanneschi et al., 2006).
If made with many stimuli and, hence, a high resolution, the
stimulus–response curve provides much information that is not
available through conventional EMG methods (Henderson et al.,
2006; Blok et al., 2007; Visser and Blok, 2009). For example, it
allows the identiﬁcation and quantiﬁcation of steps. Steps are
clearly visible size differences in the CMAP amplitude between
consecutive stimuli. These amplitude differences are larger thanf Clinical Neurophysiology,
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abrupt jumps in the usually sigmoid curve and result from the ﬁr-
ing of large, newly recruited motor unit potentials (MUPs) (Fig. 1A
and B). The presence and properties of steps and CMAP variability
throughout the curve differ signiﬁcantly between normal subjects
and patients with amyotrophic lateral sclerosis (ALS) (Henderson
et al., 2006). Hence, various properties of the curve may provide
clinically relevant information regarding MU number, MU size
and stability, and axonal excitability (Blok et al., 2007). Because
this clinically useful information is made available through a quick
assessment of the functional activity of all MUs in a muscle, we
decided to refer to the high-detail stimulus response curve as
‘‘the CMAP scan’’.
The CMAP scan can be a valuable follow-up tool for monitoring
disease progression or the speed and quality of nerve recovery in
motor neuron disease, demyelinating diseases, or following trauma
(Drenthen et al., 2008). To be able to use the CMAP scan for this
purpose, its reproducibility must be known. Assessing CMAP scan
different-day reproducibility as well as interobserver reproducibil-
ity is, therefore, the purpose of the present study.
The clinical relevance of the interobserver and different day dif-
ferences should be interpreted in perspective to the extent of CMAP
scan changes that can be found in pathological conditions, which
can be considerable. Although the latter is beyond the scope of this
study,we illustrate these pathological changes by describing typical
CMAP scans of ﬁve patients with amyotrophic lateral sclerosis (ALS)
and demyelinating neuropathies such as Guillain–Barré syndrome
(GBS) and chronic inﬂammatory demyelinating neuropathy (CIDP).
Fig. 1. (A) CMAP scan of a healthy subject. The arrow indicates the presence of a step. This step has a size of 0.28 mV, which is 2.6% of the maximum CMAP amplitude
(10.6 mV). (B) CMAP scan of an ALS patient (Patient 1). Note the presence of multiple steps, indicated by the arrows. The six steps have an absolute size of (from bottom to
top) 0.23, 0.19, 0.09, 0.09, 0.45 and 0.38 mV, respectively. The summed step size is 1.43 mV, which is 71% of the total CMAP amplitude (2.02 mV), implying that step% = 71%.
(C) Two serial CMAP scans of Patient 2 with acute-onset CIDP, made with a 1-week interval. Neither shows steps. Note the high stimulus intensities that were needed to
record the CMAP scans. Over this week, the patient deteriorated clinically and the variables in his CMAP scan worsened. The maximum CMAP amplitude decreased from 4.8 to
1.1 mV, and S5, S50, and S95 increased from 18, 26 and 36 mA to 20, 43 and 60 mA, respectively. Note the different scaling of the axes of the CMAP scans in (A)-(C).
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2.1. Subjects and design
Ten subjects (three men, seven women, age 19–37 years) with
no symptoms or signs of a neurological disease were included in
this study. Carpal tunnel syndrome was excluded by means of con-
ventional nerve conduction studies. CMAP scans were recorded on
two different days by each of two investigators who were blinded
for their own results of the previous measurement and for the re-
sults of the other investigator. The interval between the recordings
ranged from 6 to 73 days. The experimental protocol was approved
by the institutional Medical Ethics Committee. All subjects gave in-
formed consent.
The illustrative patient data were collected from patients who
participate in ongoing longitudinal studies on motor neuron dis-
ease and GBS/CIDP. Carpal tunnel syndrome was excluded in all
at the time of their inclusion. Patient 1 (53 years, female) was
diagnosed with ALS ﬁve months before her ﬁrst CMAP scan was re-
corded. Patient 2 (61 years, male) suffered from acute-onset CIDP
and was recorded twice during the acute phase with a 1-week
interval between measurements. He clinically deteriorated (pro-
gressive weakness and sensory disturbances) between the ﬁrst
and second recording. The third patient (53 years, male) suffered
from GBS ﬁve years prior to the measurement. Patient 4 (68 years,
female) was diagnosed with ALS two years prior to the measure-
ments and the last patient (60 years, female) was diagnosed with
ALS six months prior to the CMAP scans. All patients had moderate
weakness of their thenar muscles (grade 4 according to medical
research counsel (MRC) scoring).2.2. Recordings
CMAP scans were recorded using the novel CMAP scan applica-
tion on a Viking Select EMG system (CareFusion, San Diego, CA).
The CMAPs were obtained from the thenar muscles of the non-
dominant hand using 10 mm diameter, silver–silver chloride cup
electrodes. The active electrode was placed over the muscle belly
at a position that optimized the size and a steep negative offset
of the maximum CMAP. The reference electrode was placed on
the interphalangeal joint of the ﬁrst digit. The ground electrode
(self-adhesive surface electrode) was placed on the dorsum of
the hand. The median nerve was stimulated at the wrist with a
bar stimulator consisting of two 6  20 mm rectangular felt pad
electrodes with an interelectrode distance of 20 mm. The stimula-
tor was strapped to the wrist at the point where the lowest SI was
needed to stimulate the nerve. The thumb was taped to the side of
the hand to prevent signal changes due to movement and subjects
were asked to remain relaxed and silent during the recordings.
Recordings started with the determination of the lowest SI that
elicited an all or nothing response from the lowest-threshold MU
(S0) and the minimal SI at which the maximum CMAP could be re-
corded (S100). To check that all MUs were activated, the SI was
turned up by another 50%. Next, 30 stimuli, with SI decreasing
from S100 to S0 (downwards recording), were applied to ensure
that S0 and S100 were correctly set. If necessary, they were ad-
justed. Subsequently, the CMAP scan was recorded downwards
using 500 evenly spread stimuli, with a frequency of 2 Hz and
stimulus duration of 0.1 ms. To ensure that no part of the CMAP
scan was undersampled (which can occur in the steepest part of
the CMAP scan) sometimes 50–75 additional stimuli were applied.
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ment of the electrodes.
After the ﬁrst recording, all electrodes were removed before the
second investigator performed the CMAP scan. This entire proce-
dure was repeated on the second day.
2.3. CMAP scan parameters
Data were exported to Excel 2003 (Microsoft, Redmond, WA)
and subsequently imported in Matlab (version R2009b; The Math-
Works, Natick, MA) for quantitative analysis using a program that
was developed for this purpose. The parameters that were ex-
tracted from the CMAP scan were: the maximum CMAP, the SIs
that elicited 5%, 50%, and 95% of the maximum CMAP (S5, S50,
and S95, respectively), the absolute SI range (S95–S5), the relative
SI range (S95–S5)/S5) and step percentage (step%; see below).
The step analysis was semi-automated: after manual identiﬁca-
tion of the steps, the program determined their sizes (in mV). We
deﬁned steps as clear gaps in the CMAP scan that were bounded
by plateaus at the upper and lower end of the gap, each of which
consisted of at least three consecutive responses of about the same
size (i.e., disregarding noise). The step% variable is deﬁned as the
sum of the step sizes of all steps in a CMAP scan, relative to the
maximum CMAP amplitude. For the SI parameters we used S5
and S95 rather than S0 and S100 to minimize the inﬂuence of
noise. The maximum CMAP, S5, S50, S95 and the SI ranges were
automatically determined by the program.
2.4. Statistical analysis
SPSS (version 15.0.1; SPSS Inc., Chicago, IL) was used for statis-
tical analysis of the data. Data were tested for normality withFig. 2. (A). Four CMAP scans (two per investigator) of a healthy subject. The CMAP scan
CMAP scans of Investigator 2 are shifted slightly more towards the right as a result of th
shapes are very similar. Step% ranged from 12% to 15% between the four CMAP scans. (B)
Investigator 1 in Patient 3 who had suffered from GBS ﬁve years earlier and was now sta
two repeated CMAP scans in two ALS patients (Patients 4 and 5). The CMAP scans we
reproduce well, with step% of 75% for both CMAP scans in (C) and 41% for both CMAP sKolmogorov–Smirnov tests. Since all parameters were normally
distributed, parametric tests were used. The 20 paired observations
(ten on two days per investigator) were used to assess interob-
server reproducibility by means of the coefﬁcients of variation
(CoV) and intraclass correlation coefﬁcients (ICC) calculated with
a two-way random effects model with single measure (model: 2,
1). Paired t-tests were used to test for signiﬁcant differences be-
tween the two investigators. A p-value <0.05 was considered to
be statistically signiﬁcant. Finally, we determined how far apart
(on average) two paired recordings were, disregarding whether
investigator 1 or investigator 2 obtained the larger value. For this
purpose, the mean of the absolute values of the difference between
the paired measurements was calculated.
Absolute and relative different-day reproducibility in the ten
subjects was tested using the ICC, the CoV and upper limits of dif-
ferences based on Bland–Altman (dþ 2Sd; d = mean of the differ-
ences, Sd = standard deviation of the differences) (Bland and
Altman, 1986). The CoVs were calculated for all parameters except
for the step percentage, since several individual values of step per-
centage equaled zero.3. Results
In total, 40 CMAP scans were recorded in the ten healthy sub-
jects. All were of good quality (adequately sampled, good signal-
to-noise ratio and no movement artefacts). Fig. 2A shows the four
CMAP scans recorded in one of the healthy subjects. The scans in
black were performed by Investigator 1 and those in grey by Inves-
tigator 2. The CMAP scans of Investigator 2 are shifted slightly
more towards the right as a result of systematically higher SI val-
ues for Investigator 2 (see below).s in black are performed by Investigator 1 and those in grey by Investigator 2. The
e systematically higher SI values for Investigator 2. Despite this slight variation, the
Example of three repeated CMAP scans (black, grey, light grey; same day) made by
ble. Note the broad shape of the CMAP scan (high SI range). (C) and (D) Examples of
re performed on the same day by Investigator 2. Shapes are similar and the steps
cans in (D). Note the different scaling of the axes of the CMAP scans in (A)–(D).
Table 1
Interobserver effects on CMAP scan variables.
Parameter Mean (SD) Investigator 1 Mean (SD) Investigator 2 Mean difference* p-value CoV (%) ICC
Maximum CMAP (mV) 12.8 (2.9) 12.4 (2.9) 1.3 0.28 6 0.83
S5 (mA) 7.3 (2.0) 8.3 (2.3) 1.3 <0.01 10 0.80
S50 (mA) 8.6 (2.0) 9.9 (2.2) 1.5 <0.01 11 0.76
S95 (mA) 9.6 (2.3) 11.6 (2.5) 1.9 <0.01 13 0.72
Range (mA) 2.7 (1.1) 3.4 (1.4) 0.7 <0.01 15 0.80
Relative range 0.4 (0.3) 0.5 (0.4) 0.1 0.11 7 0.87
Step percentage (%) 3.9 (4.0) 4.5 (4.2) 1.9 0.24 NTa 0.84
a NT = not tested because several individual values equal 0.
* Mean of the absolute values of the differences between the paired measurements.
Table 2
Different-day effects on CMAP scan variables (for Investigator 1).
Parameter Upper limit of difference CoV (%) ICC
Maximum CMAP (mV) 3.0 8 0.91
S5 (mA) 2.6 8 0.84
S50 (mA) 2.5 8 0.84
S95 (mA) 3.1 8 0.83
Range (mA) 1.4 3 0.87
Relative range 0.2 10 0.94
Step percentage (%) 4.7 NTa 0.86
a NT = not tested because several individual values equal 0.
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tor are summarized in Table 1. There was a small but signiﬁcant
difference in the SI parameters S5, S50, S95, and absolute range be-
tween the two investigators, with consistently higher values for
Investigator 2. The largest difference was found for S95 (mean dif-
ference 1.9 mA). The relative range, maximum CMAP and step per-
centage did not differ signiﬁcantly between the investigators. The
ICCs for the interobserver reproducibility varied between 0.72
(for S95) and 0.87 (for relative range), the CoVs between 6% (for
maximum CMAP) and 15% (for range).
Table 2 presents the upper limits of differences, the CoVs and
the ICCs for the different-day reproducibility of Investigator 1.
The results for Investigator 2 were similar. The lowest ICC was
0.83 for S95, the highest was 0.94 for relative range.
Figs. 1 and 2 present the CMAP scans of the ﬁve patients. The
ALS patients (Figs. 1C, 2C and D) showed a higher step% (71%,
75% and 41%, respectively) than the healthy subjects (Figs. 1A
and 2A; 2.6% and 12%, respectively) and patients with a demyelin-
ating neuropathy (Figs. 1B and 2B; 0% and 24%, respectively). The
latter patients showed increased SI ranges (‘broader’ CMAP scans),
a ﬁnding that probably reﬂects decreased nerve excitability.4. Discussion
This study shows that, in healthy subjects and with two well-
trained investigators, the interobserver reproducibility and the
different-day reproducibility of all investigated variables are good.
They appear to be in the same range as the reproducibility of other
electrophysiological variables, such as CMAP amplitude, nerve con-
duction velocity, and distal motor latency. (Kohara et al., 1999;
Kong et al., 2006; Pinheiro et al., 2008). Fig. 2 illustrates that not
only the parameters of the CMAP scan reproduce well, but also
their overall shapes. Furthermore, the upper limits to the differ-
ences found with different-day recordings are small compared to
the pathophysiological changes that can often be observed in serial
CMAP scans in patients.
In this study we have shown typical examples of CMAP scans,
recorded from ﬁve patients with ALS, GBS or CIDP (Figs. 1 and 2).
These are in concordance with the few clinical studies on the CMAPscan that thus far have been published. Henderson et al., 2006 have
reported that ALS patients had more and larger steps in their CMAP
scans than healthy subjects, as a sign of a decrease in MU number
and/or increase in MU size. We have previously presented clear
abnormalities in stimulus intensity variables (similar to those in
Figs. 1C and 2B) in CMAP scans of acute-phase and late-phase
GBS patients. (Drenthen et al., 2008) Typical numerical values for
the variables in these and other pathologies have been published
as supplementary material to (Blok et al., 2007) and agree with val-
ues presented in this study. We conclude that the day-to-day var-
iability of the CMAP scan in healthy subjects is relatively small
compared to the pathophysiological changes that can be found in
ALS and demyelinating neuropathies. This makes the CMAP scan
a potentially sensitive tool for follow-up studies.
4.1. Interobserver reproducibility
Neither the maximum CMAP nor the step percentage differed
signiﬁcantly between the investigators. This indicates that the
positioning of the recording electrodes is not very sensitive to
subjective factors. The interobserver ICCs for S50 and S95 were,
however, relatively low, probably because of a small systematic
difference in these variables between the two investigators.
Considering that the SIs depend strongly on the relative location
of the stimulus electrodes to the axons in the nerve trunk, the most
likely explanation for this bias is that the stimulus electrode posi-
tioning of Investigator 2 was slightly less optimal. For longitudinal
studies that aim to detect small changes in SI parameters, this ﬁnd-
ing implies that it is preferable for CMAP scans to be recorded by
the same investigator. Finally, the relative range corrects for the
abovementioned bias and, therefore, showed no signiﬁcant differ-
ence between the investigators. However, compared to the direct
measures S5, S50, S95 and absolute range, the relative range is less
easy to interpret and possibly less sensitive.
4.2. Different-day reproducibility
All parameters had a good different-day reproducibility with
ICCs >0.8 and CoVs <15%. Different-day reproducibility of the SI
parameters was better than the interobserver reproducibility,
conﬁrming that reproducibility increases when recordings are
performed by the same investigator. That the reproducibility is
good also appears from the low upper limits of differences, partic-
ularly those of the SI parameters (Table 2). These upper limits
represent the maximum difference between measurements that
can be expected as a result from normal variability in healthy
subjects. Changes beyond these limits are likely to result from
pathological changes or recovery processes. In this context it
should be emphasized, however, that these small limits can only
be reached with careful optimal placement of the stimulation
electrodes, which requires some time and experience of the
investigator.
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Although this study provides evidence for a good reproducibil-
ity of all parameters in healthy subjects, this does not necessarily
imply that our ﬁndings are also valid for patients. Nevertheless,
with respect to the variability in the SI variables, we believe that
our current ﬁndings pertain at least roughly to pathological condi-
tions as well, for the following reasons. First, we noted that in
healthy subjects the variability in SI variables mainly depends on
minor changes in (sub)cutaneous tissue impedance, the distance
between the stimulator and the nerve, and possibly on nerve diam-
eter. It is not likely that these factors are greatly inﬂuenced by the
diseases of the investigated patients. Second, repeated recordings
in patients suggest a similar variability as in healthy subjects. For
example, Fig. 2B shows repeated CMAP scans made by Investigator
1 on a single day in a stable patient who had suffered from Guil-
lain–Barré syndrome a few years earlier.
The variability in the steps mainly depends on noise and alter-
nation. Because steps are larger in patients undergoing reinnerva-
tion processes (Fig. 1B), the signal-to-noise (step-to-noise) ratio
may be expected to go up in these conditions, and when fewer mo-
tor units are present, alternation would be reduced. Hence, we
anticipate that the reproducibility of step percentage is at least
as good in patients as in healthy subjects (Henderson et al.,
2006). The examples in Fig. 2C and D support this notion. However,
the upper limit of differences in step percentage as presented in
Table 2 may not apply for patients, because this percentage tends
to be very low in healthy subjects. In this context, we would like
to add that it is not uncommon for steps to be found in CMAP scans
of healthy subjects. These steps mostly occur in the very high or
low end of the scan, where there is little alternation. The all-or-
nothing response of a single MU to a stimulus then causes an easily
noticeable ‘jump’ in the CMAP amplitude. Steps that are found in
healthy conditions may also be due to the physiological existence
of a few large MUs and/or the normal ageing process. (Doherty
and Brown, 1993).
We conclude that the CMAP scan reproducibility is good. Our
results suggest that the CMAP scan as a follow-up tool is suitable
to detect (patho)physiological changes in the studied variables.Acknowledgements
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